Vaxcyte stock jumps on new executives, VAX-31 data timeline

Vaxcyte Inc (NASDAQ:PCVX) shares experienced a 6.3% increase in after-hours trading on Thursday, following the company's announcement of two new senior leadership roles and a revised timeline for its VAX-31 vaccine trial data. The vaccine developer added Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer to its executive team.

Jodar, who previously worked at Pfizer for 17 years, primarily focused on vaccine development, including key products like Prevnar 13 and Comirnaty. McAvoy, with over 30 years of legal experience in biopharmaceuticals, most recently served as Executive Vice President and Chief Legal Officer at Teva Pharmaceutical Industries Ltd. The VAX-31 adult Phase 3 OPUS-1 trial, which has six trials involving 6,191 adult participants, will now provide safety, tolerability, and immunogenicity data by the end of October 2026, instead of the previously estimated fourth quarter of 2026.

Further safety, tolerability, and immunogenicity results from the OPUS-2 and OPUS-3 Phase 3 trials are expected in the first half of 2027.